Abstract
Primary sclerosing cholangitis (PSC) is a frequently progressive and fatal disease. Death from cancer occurs in a significant subset of patients with PSC. Patients with PSC have a 10 to 15 % lifetime risk of developing cholangiocarcinoma (CCA). About one third of CCAs are present in the first year after a diagnosis of PSC; the remainder are present with a frequency of about 1.5 % each year. Patients with concomitant PSC and inflammatory bowel disease (IBD) have a 4-fold higher risk of colorectal cancer (CRC) than patients with IBD alone and a 10-fold higher risk of CRC than the general population. The risk does not diminish with liver transplantation. This patient population also has a high frequency of carcinoma in gallbladder mass lesions. The risk for hepatocellular carcinoma (HCC) in the presence of cirrhosis is uncertain—two large cohort studies suggest that HCC is not as common as in other causes of cirrhosis. Although AASLD guidelines do not recommend routine screening for liver tumors in patients with PSC, we recommend MRI/MRCP and serum CA 19-9 levels in patients with PSC every 6 months to screen for CCA, HCC, pancreatic cancer, and gallbladder cancer. Screening colonoscopy at the diagnosis of PSC and surveillance colonoscopies every 1–2 years should be performed in those with PSC and IBD.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic syndrome of unknown etiology characterized by fibrosing inflammatory destruction of the intra- and extrahepatic bile ducts. It is frequently progressive and may be fatal in the absence of liver transplantation. Inflammatory bowel disease (IBD) is associated with PSC in approximately 70 % of patients [1•] and frequently precedes clinical recognition of hepatobiliary disease.
Death from cancer occurs in a significant subset of patients with PSC. Although cholangiocarcinoma (CCA) is the cancer most frequently associated with PSC, other cancers are recognized as part of the disease spectrum. In a study of 200 PSC patients followed for over a decade in Belgium, CCA developed in thirteen patients, colorectal cancer developed in ten, hepatocellular carcinoma developed in three, and pancreatic cancer developed in five. In all, 61 patients died, 28 of them from cancer [2•]. In another large cohort of 604 Swedish patients with PSC with a median follow-up of 5.7 years (range 0–27.8 years), 171 patients died, 44 % of them from cancer. The risk of CCA was 160-fold greater than in the general population, and 37 % of CCAs were diagnosed less than 1 year after the diagnosis of PSC [3]. A retrospective analysis of more than 500 patients with PSC in Germany found that cholangiocarcinoma accounted for 75 % of all tumors with 20 % of patients receiving the diagnosis at first presentation or within the first year of diagnosis of PSC [4•]. This study also reported a very low incidence of hepatocellular carcinoma (HCC) in patients with PSC.
A second major concern in patients with PSC is colorectal cancer (CRC). Patients with PSC-IBD have a 4-fold higher risk of CRC than patients with IBD alone and a 10-fold higher risk of colorectal cancer than the general population [5]. A recent analysis of the English literature reported a risk of CRC in up to 30 % of patients followed for 20 years after the diagnosis of PSC-IBD [1•]. The authors also pointed out that the pathogenesis and optimal screening of these patients remain uncertain.
Although many issues remain unresolved, the following review will give an overview of common malignancies seen in this patient population and will suggest reasonable cancer surveillance strategies for PSC patients.
Cholangiocarcinoma
Patients with PSC have a 10 to 15 % lifetime risk of developing CCA, i.e., a 398-fold increased risk for developing CCA compared to the general population [6•]. Unlike hepatocellular carcinoma, CCA may occur in the absence of advanced hepatic fibrosis, and the incidence increases steadily after the first year, with no late rise in frequency [7]. In fact, many patients are diagnosed with CCA early in their fourth decade of life [2•, 6•]. In a series of 161 patients from the Mayo Clinic, 7 % developed CCA during a mean follow-up period of 11.5 years, and no association was found between the duration of PSC and the incidence of CCA [7].
A substantial portion of patients with CCA are diagnosed soon after their PSC diagnosis with some studies reporting 30 % in the first year after PSC diagnosis [2•]. This finding suggests that superimposed CCA may have elicited the symptoms leading to the diagnosis of PSC.
Cholangiocarcinoma has a dismal prognosis with some reporting a median survival as low as 5 months after diagnosis [8]. A large Dutch population-based study identified 590 patients with PSC with a median follow-up of 92 months. CCA occurred in 41 patients (7 %) of whom 33 died (80 %) after a median period of 1 year. The cumulative risk of CCA after 10, 20, and 30 years was 6, 14 and 20 %, respectively, contradicting the notion of time-independent risk reported above [6•].
The diagnosis of cholangiocarcinoma is usually based on the appearance of symptoms, commonly the onset of jaundice. These patients typically have unresectable tumors and a very bad prognosis -only 10 % survive past 2 years [9]. Distinguishing between a benign and a malignant dominant stricture is challenging in patients with PSC. A single tertiary center in London reported their 25-year experience with PSC-related dominant strictures. A total of 128 patients with PSC were followed for a mean of 9.8 years. The mean survival of those with dominant strictures (13.7 years) was worse than those without dominant strictures (23 years). Much of the survival difference was related to a 26 % risk of cholangiocarcinoma developing in those with dominant strictures. Nearly half of CCAs were diagnosed within 4 months of the diagnosis of PSC. The mean CA 19-9 was 8236 IU/L in those with CCA and 97 IU/L with benign dominant strictures [10•].
The efficacy of tumor markers for early diagnosis of CCA in patients with PSC has not been established. A recent study of 208 patients found a sensitivity and specificity of 78 and 98 %, respectively, using a CA 19-9 value of 129 U/mL as a cutoff value [11]. However, more than one third with this cutoff did not have cholangiocarcinoma after an average period of 30 months of follow-up [12•]. CA 19-9 also requires the presence of the Lewis blood group antigen. Individuals with a negative Lewis phenotype (estimated at 5 to 10 % of the population) do not make CA 19-9 and will not benefit from this testing.
For patients requiring endoscopic retrograde cholangiopancreatography (ERCP), routine brush cytology analysis alone detects CCA with low levels of sensitivity (40 % or less), but specificity is nearly 100 % [13]. Fluorescence in situ hybridization (FISH) may be more sensitive and as specific as cytology [14]. Among patients with PSC and a dominant stricture, the presence of polysomy identified those with an eventual diagnosis of CCA with 88 % specificity [15].
The American Association for the Study of Liver Diseases (AASLD) does not recommend routine cholangiocarcinoma surveillance in PSC patients except for those with deteriorating constitutional performance status or liver biochemical tests [13]. This nihilistic approach is based on the absence of proven benefit of early detection and surgical or medical management of patients with CCA. Since late CCA is rapidly fatal, we recommend combining serum CA 19-9 measurements with imaging to improve our ability to detect worrisome extrahepatic strictures that could be cholangiocarcinoma. ERCP with brush cytology and FISH should be reserved for patients with dominant strictures, a rising CA 19-9, or an increase in cholestatic liver tests.
Colorectal Carcinoma
PSC is associated with inflammatory bowel disease (IBD) in approximately 70 % of patients [1•], and patients with ulcerative colitis (UC) and PSC are at increased risk of colorectal dysplasia and carcinomas compared with UC alone, with OR 4.79 (95 % CI 3.458–6.41) [5]. Some data suggest the risk of CRC development can reach up to 30 % at 20 years after a diagnosis of concurrent IBD and PSC [16].
A large population-based study in the Netherlands followed 590 patients with PSC with a median follow-up of over 7 years. Twenty of 590 patients developed colorectal carcinoma (CRC), and all but one had a diagnosis of inflammatory bowel disease. There was a 5-fold increased risk for developing CRC in all PSC patients compared to age and gender-matched general population and a 9-fold increased risk compared to UC patients alone. CRC occurred at a much younger age in PSC-IBD patients compared to IBD controls (median age 39 compared to 59) [6•]. The cumulative risk of CRC or dysplasia was 4.1 % at 5 years, 5.4 % at 10 years, and 9.3 % at 20 years after the detection of PSC [2•]. Given the increased risk of CRC in patients with PSC, the AASLD recommends surveillance colonoscopy with biopsies at 1- to 2-year intervals from the time of diagnosis of PSC in patients with concomitant IBD and an initial full colonoscopy with biopsies for those with a new diagnosis of PSC in the absence of a previous diagnosis of IBD [13].
The risk of active colitis and colon cancer do not decrease after liver transplantation. Patients with PSC-IBD have a high risk of de novo CRC after OLT, approximately ten times the risk of all other patients undergoing OLT [17•] and up to 20-fold higher than risk in the general population [18]. According to an analysis of 439 patients with PSC who underwent OLT between 1984 and 2006 in the Nordic OLT registry, the risk of CRC was higher after OLT than before with a hazard ratio of 1.9, not entirely explained by the duration of IBD [19•]. In contrast, Hanouneh et al. from the Cleveland Clinic performed a case-control analysis of patients with PSC and IBD who underwent OLT (n = 43) compared to those who did not receive a transplant. The rate of colonic neoplasia was similar in the IBD/PSC/OLT group compared to the IBD/PSC/no-OLT group (34 % versus 30 %, p = 0.24) but higher in PSC patients compared to those with other forms of chronic liver disease (34 % versus 0 %, p = 0.018) [20•]. The development of post-OLT colonic neoplasia did not translate to decreased survival post-transplant in patients with IBD and PSC.
The use of ursodeoxycholic acid (UDCA) as a chemopreventive agent in patients with PSC and IBD is controversial with some studies showing benefit [21, 22] and others showing no difference [23]. A meta-analysis of eight studies including 177 cases of colorectal neoplasia in 763 patients with PSC-IBD reported a significant chemopreventive effect of UDCA on the risk of colorectal cancer and/or high-grade dysplasia with OR of 0.35 (95 % CI 0.17–0.73) [24•]. A subgroup analysis showed low-dose UDCA use (8 to 15 mg/kg/day) was also associated with a significant risk reduction of colorectal neoplasia. A nested cohort study from 2011 demonstrated an increased risk of colorectal cancer associated with high-dose UDCA in PSC patients [25•]. Fifty-six subjects with PSC and UC were followed for a total of 235 patient years. Patients who received high-dose UDCA (28–30 mg/kg/day) had a significantly higher risk of developing colorectal neoplasia (dysplasia and cancer) compared to the placebo group (hazard ratio 4.4, CI 1.30–20.1, p = 0.02) [25•]. AASLD recommends against the use of UDCA in all patients with PSC including those with PSC-IBD [13] whereas EASL (European Association for the Study of the Liver) recommends UDCA in high-risk groups such as those with a strong family history of CRC, previous colorectal dysplasia, or long-standing extensive colitis [26].
Given the increased risk of colorectal cancer in patients with PSC and IBD, we recommend surveillance with colonoscopies starting at the time of diagnosis of PSC with repeat colonoscopy every 1 to 2 years as recommended by both EASL and AASLD. Surveillance colonoscopy should continue after liver transplantation because the risk of colorectal cancer appears to be unaffected or worsened by OLT. The data regarding the chemopreventive effects of UDCA are mixed; we do not recommend the routine use of UDCA for chemoprevention in PSC patients.
Gallbladder Carcinoma
The prevalence of gallbladder carcinoma in patients with PSC is estimated at 3 to 14 % [27•]. Gallbladder abnormalities were assessed in 286 patients with PSC treated in Sweden between 1970 and 2005. One or more gallbladder abnormalities were found in 41 % of the patients. A gallbladder mass lesion, mean size of 21 mm, was found in 18 patients (6 %)—gallbladder carcinoma was confirmed in ten (56 %) of these patients. Histological reevaluation disclosed epithelial dysplasia of the gallbladder in nine patients without a gallbladder mass lesion [28].
In another review of 102 patients with PSC who underwent cholecystectomy at the Mayo Clinic between 1977 and 1999, a gallbladder mass was found in 14 patients (14 %). Eight of these had adenocarcinoma (57 %) and six had benign masses. In those with benign masses, 33 % had associated epithelial cell dysplasia. Only seven of the mass lesions were recognized preoperatively, and no significant difference in size was found between malignant or benign lesions.
The high frequency of carcinoma in gallbladder mass lesions indicates that surveillance with regular ultrasound may be of value in these patients. AASLD guidelines from 2010 recommend an annual ultrasound to detect mass lesions in the gallbladder and cholecystectomy for any size polyps in patients with PSC [13]. However, a second retrospective review of PSC patients who underwent cholecystectomy from the Mayo Clinic argues that observation may be appropriate for gallbladder polyps <0.8 cm. The most common indication for cholecystectomy in this 57 patient cohort was gallbladder polyp or mass. Sensitivity and specificity of a gallbladder lesion of 0.8 cm and the presence of gallbladder neoplasia was 100 and 70 %, respectively. Twenty-three patients (40 %) had an early post-operative complication and nearly 35 % of those had more than one complication. Child-Pugh score was the only predictor of post-operative outcomes in the multivariate model [29]. The authors concluded that gallbladder polyps <0.8 cm are unlikely to be malignant, and observation may be appropriate in the absence of other concerning features such as new or enlarging lesions, large masses, adjacent wall thickening, sessile morphology, or an arterial signal on Doppler.
We agree with the AASLD and recommend annual screening for gallbladder cancer with ultrasound.
Hepatocellular Carcinoma
The incidence of HCC in patients with PSC cirrhosis has not been established, but many experts believe it to be below the 1.5 % per year threshold required to institute HCC surveillance. A German retrospective study analyzed the risk of hepatocellular carcinoma (HCC) in 509 patients with PSC, 119 of whom had cirrhosis. Data were collected from periods up to 33 years with a total of 4202 patient-years included in the final analysis. In 292 patient-years under cirrhosis risk, not a single HCC was detected. In reviewing 140 liver explants, no incidental HCC was detected in the series. In contrast to the low numbers of HCC, 35 patients developed cholangiocarcinoma, 3 patients developed gallbladder cancer, and 9 patients developed colorectal cancer [4•]. These data suggest the risk of HCC, even in the presence of cirrhosis, is lower than the limit generally accepted for regular surveillance examinations using ultrasound. We are concerned that a study of 119 patients with PSC and cirrhosis is too small a cohort to change our HCC screening practices. AASLD has no guidelines on HCC screening in patients with PSC and cirrhosis since no supporting evidence exists. We screen cirrhotic patients with PSC with imaging every 6 months—HCC screening is addressed by the same images.
Conclusion
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic syndrome with severe complications that frequently lead to serious health issues, liver transplantation, and/or death. Inflammatory bowel disease (IBD) is associated with PSC in approximately 70 % of patients [1•] and often precedes clinical recognition of hepatobiliary disease. Death from cancer occurs frequently in patients with PSC, and many studies have shown malignancy to be the most common cause of death.
Compared to the general population, the risk of cholangiocarcinoma, gallbladder cancer, and colorectal cancer (specifically in patients with PSC-IBD) is high. Despite this, the value of screening for various cancers has not been adequately studied. As a practical guide, and in the absence of definitive studies, we recommend MRI every 6 months with CA19-9 and AFP to screen for HCC and CCA. We also recommend ultrasound of the gallbladder every year to screen for gallbladder masses since ultrasound is more sensitive than MRI for this diagnosis. Finally, we recommend routine surveillance for CRC in patients with inflammatory bowel disease and a screening colonoscopy to exclude ulcerative colitis in all patients with newly diagnosed PSC.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8. doi:10.1016/j.jhep.2011.10.025. A systemic search of literature was performed in MEDLINE and EMBASE for population-based epidemiological studies reporting incidence and/or prevalence rates for PSC or PBC. Literature yielded 2286 abstracts of which 31 articles fulfilled inclusion critieria. Overall the authors concluded that incidence and prevalence rates of both PSC and PBC vary widely and seem to be increasing.
Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. Liver Int. 2012;32(2):214–22. doi:10.1111/j.1478-3231.2011.02575.x. Two hundred patients with PSC were followed to analyze morbidity and mortality. Malignancies developed in 20% of which 45.9% led to death.
Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. 2002;36:321–7.
Zenouzi R, Weismüller TJ, Hübener P, et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(10):1733–8. doi:10.1016/j.cgh.2014.02.008. This is a retrospective study of patients with well-defined PSC. Data were collected from periods of up to 33 years. 119 patients with cirrhosis were identified. During 292 patient-years, none of these patients developed HCC.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54. doi:10.1067/mge.2002.125367.
Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55. doi:10.1002/hep.26565. Four independent Dutch hospital databases were searched comprising 50% of the population. Five hundred and ninety PSC patients were identified and median follow up was 92 months. CRC risk was 10-fold increased compared to ulcerative colitis controls.
Burak K, Angulo P, Pasha T, Egan K, Petz J, Lindor K. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6. doi:10.1111/j.1572-0241.2004.04067.x.
Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. 1991:21–5. doi:10.1097/00000658-199101000-00004.
Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc. 1994;69:969–82.
Chapman MH, Webster GJM, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012;24(9):1051–8. doi:10.1097/MEG.0b013e3283554bbf.
Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734–40. doi:10.1007/s10620-005-2927-8.
Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9:434.e1–9.e1. doi:10.1016/j.cgh.2011.02.007. The authors analyzed data from all Mayo Clinic patients with PSC and serum levels of CA 19-9 greater than 129 U/mL from 2000–2010. Thirty-seven percent of patients reviewed had no evidence of CCA after a median follow-up time of 30 months.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78. doi:10.1002/hep.23294.
Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99:1675–81. doi:10.1111/j.1572-0241.2004.30281.x.
Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010;51:174–80. doi:10.1002/hep.23277.
Wang R, Leong RW. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol. 2014;20(27):8783–9. doi:10.3748/wjg.v20.i27.8783.
Singh S, Varayil JE, Jr EVL, Talwalkar JA. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and. 2013:1361–9. doi:10.1002/lt. This is a systematic review of cohort studies reporting the incidence of de novo CRC after OLT for PSC. The authors concluded that the risk of CRC remains high for patients who undergo OLT for PSC, particularly in the subset of patients with associated IBD.
Sint Nicolaas J, de Jonge V, Steyerberg EW, Kuipers EJ, van Leerdam ME, Veldhuyzen-van Zanten SJO. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant. 2010;10(4):868–76. doi:10.1111/j.1600-6143.2010.03049.x.
Jorgensen KK, Lindstrom L, Cvancarova M, et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol. 2012;47:1021–9. This is a multicenter study within the Nordic Liver Transplant Group that assessed the risk of colorectal neoplasia by using the competing risk aggression analysis. The authors reported the cumulative risk of colorectal neoplasia was higher after than before OLT.
Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2012;18(2):269–74. doi:10.1002/ibd.21692. The authors identified patients with IBD/PSC who underwent OLT from 1998–2005. They concluded patients with IBD/PSC have a similar rate of colon neoplasia compared to those who did not have OLT. Also, the rate of colon neoplasia in OLT recipients was higher in PSC patients compared to those with other forms of chronic liver disease.
Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95.
Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–93. doi:10.1053/gast.2003.50156.
Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22:783–8. doi:10.1111/j.1365-2036.2005.02650.x.
Singh S, Khanna S, Pardi DS, Loftus EV, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(8):1631–8. doi:10.1097/MIB.0b013e318286fa61. The authors conducted a systematic review of literature dealing with ursodeoxycholic acid (UDCA) and its effect on IBD-associated CRC. Meta-analysis showed no significant protective associated between UDCA use and CRN. In a subgroup analysis, low-dose UDCA use was associated with significant risk reduction of colorectal neoplasia.
Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106:1638–45. doi:10.1038/ajg.2011.156. Fifty-six patients with PSC were followed for 235 patient years. Patients who received high-dose UDCA had a significantly higher risk of developing colorectal neoplasia compared to those who received placebo.
Beuers U, Boberg K, Chapman R, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67. doi:10.1016/j.jhep.2009.04.009.
Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54(5):1842–52. doi:10.1002/hep.24570. The authors review the risk of CCA, gallbladder cancer, HCC and CRC in patients with PSC.
Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598–605. doi:10.1016/j.jhep.2007.11.019.
Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol. 2012;107(3):431–9. doi:10.1038/ajg.2011.361.
Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924–33. doi:10.1056/NEJM199504063321406.
Compliance with Ethics Guidelines
Conflict of Interest
Saira A. Khaderi and Norman L. Sussman declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Liver
Rights and permissions
About this article
Cite this article
Khaderi, S.A., Sussman, N.L. Screening for Malignancy in Primary Sclerosing Cholangitis (PSC). Curr Gastroenterol Rep 17, 17 (2015). https://doi.org/10.1007/s11894-015-0438-0
Published:
DOI: https://doi.org/10.1007/s11894-015-0438-0